Combined aliskiren and l-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 1, 2015, Pages 65-76

  Santuzzi, C H ^a   Tiradentes, R V ^a   Mengal, V ^a   Claudio, E R G ^a   Mauad, H ^a   Gouvea, S A ^a   Abreu, G R ^a  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

2K1C hypertension; Aliskiren; Endothelial dysfunction; L arginine; RAAS and oxidative stress

Indexed keywords

ALISKIREN; ARGININE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; LOSARTAN; VASCULOTROPIN RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD VESSEL REACTIVITY; ENDOTHELIAL DYSFUNCTION; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84916920256     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20144191     Document Type: Article

References (34)

1. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension 1999; 34: 782-789. doi: 10.1161/01.HYP.34.4.782
2. Yu TT, Guo K, Chen HC, Lan CZ, Wang J, Huang LL, et al. Effects of traditional Chinese medicine Xin-Ji-Er-Kang formula on 2K1C hypertensive rats: role of oxidative stress and endothelial dysfunction. BMC Complement Altern Med 2013; 13: 173. doi: 10.1186/1472-6882-13-173
3. Basile DP, Donohoe DL, Phillips SA, Frisbee JC. Enhanced skeletal muscle arteriolar reactivity to ANG II after recovery from ischemic acute renal failure. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1770-R1776. doi: 10.1152/ajpregu.00269.2005
4. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-442. doi: 10.1161/01.RES.0000180753.63183.95
5. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962. doi: 10.1056/NEJMoa013591
6. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009; 302: 148-158. doi: 10.1016/j.mce.2008.11.003
7. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009; 157: 527-536. doi: 10.1111/j.1476-5381.2009.00240.x.
8. Toblli JE, DiGennaro F, Giani JF, Dominici FP. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag 2012; 8: 151-160. doi: 10.2147/VHRM.S20669
9. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Fouryear persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23: 1999-2010. doi: 10.1016/S0149-2918(01)80152-1
10. Savvatis K, Westermann D, Schultheiss HP, Tschope C. First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integr Blood Press Control 2010; 3: 163-170
11. Duprez DA, Davis P, Botha J. The Ageless Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients =65 years of age with systolic hypertension. Circulation 2008; 118: S-886-S-887
12. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143. doi: 10.1161/01.HYP.0000101688.17370.87
13. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018. doi: 10.1161/01.CIR.0000156466.02908.ED.
14. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425. doi: 10.1161/CIRCULATIONAHA.107.750745
15. Gouvêa SA, Moysés MR, Bissoli NS, Pires JG, Cabral AM, Abreu GR. Oral administration of L-arginine decreases blood pressure and increases renal excretion of sodium and water in renovascular hypertensive rats. Braz J Med Biol Res 2003; 36: 943-949. doi: 10.1590/S0100-879X2003000700017
16. Jabecka A, Ast J, Bogdaski P, Drozdowski M, Pawlak-Lemaska K, Cielewicz AR, et al. Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, Lcitruline, L-arginine and antioxidant status. Eur Rev Med Pharmacol Sci 2012; 16: 1665-1674
17. Gokce N. L-arginine and hypertension. J Nutr 2004; 134: 2807S-2811S.
18. Gouvea SA, Bissoli NS, Moysés MR, Cicilini MA, Pires JG, Abreu GR. Activity of angiotensin-converting enzyme after treatment with L-arginine in renovascular hypertension. Clin Exp Hypertens 2004; 26: 569-579. doi: 10.1081/CEH-200031837
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
20. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587. doi: 10.1161/hy09t1096249
21. Ceron CS, Castro MM, Rizzi E, Montenegro MF, Fontana V, Salgado MC, et al. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010; 160: 77-87. doi: 10.1111/j.1476-5381.2010.00678.x.
22. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 2004; 109: 1795-1801. doi: 10.1161/01.CIR.0000124223.00113.A4
23. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923. doi: 10.1172/JCI118623
24. Silva BR, Pernomian L, Grando MD, Amaral JH, Tanus-Santos JE, Bendhack LM. Hydrogen peroxide modulates phenylephrine-induced contractile response in renal hypertensive rat aorta. Eur J Pharmacol 2013; 721: 193-200. doi: 10.1016/j.ejphar.2013.09.036
25. Hiyoshi H, Yayama K, Takano M, Okamoto H. Angiotensin type 2 receptor-mediated phosphorylation of eNOS in the aortas of mice with 2-kidney, 1-clip hypertension. Hypertension 2005; 45: 967-973. doi: 10.1161/01.HYP.0000164571.77710.19
26. Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther 2013; 140: 239-257. doi: 10.1016/j.pharmthera.2013.07.004
27. Savoia C, Arrabito E, Parente R, Sada L, Madaro L, Nicoletti C, et al. The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes. Clin Sci 2013; 125: 183-189. doi: 10.1042/CS20120395
28. Zhang W, Han Y, Meng G, Bai W, Xie L, Lu H, et al. Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats. J Am Heart Assoc 2014; 3: e000606. doi: 10.1161/JAHA.113.000606
29. Sun J, Druhan LJ, Zweier JL. Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. Arch Biochem Biophys 2010; 494: 130-137. doi: 10.1016/j.abb.2009.11.019
30. Alvarez Y, Briones AM, Hernanz R, Perez-Giron JV, Alonso MJ, Salaices M. Role of NADPH oxidase and iNOS in vasoconstrictor responses of vessels from hypertensive and normotensive rats. Br J Pharmacol 2008; 153: 926-935. doi: 10.1038/sj.bjp.0707575
31. Amaral LM, Pinheiro LC, Guimaraes DA, Palei AC, Sertorio JT, Portella RL, et al. Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. J Cell Mol Med 2013; 17: 1300-1307. doi: 10.1111/jcmm.12106
32. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148. doi: 10.1161/01.RES.74.6.1141
33. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003; 42: 1075-1081. doi: 10.1161/01.HYP.0000100443.09293.4F.
34. Touyz RM, Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 2004; 122: 339-352. doi: 10.1007/s00418-004-0696-7.